MYOMO, INC. (MYO) FY2025 10-K Annual Report
MYOMO, INC. (MYO) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 9, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
MYOMO, INC. FY2025 10-K Analysis
Business Overview
- • Core business: Wearable myoelectric-controlled upper limb orthoses for neuromuscular disorders and paralysis
- • New emphasis on upcoming MyoPro3 and MyoPal pediatric device to expand product lineup
- • Strategic shift toward broader direct billing and increased sales through O&P providers and international markets, including EU and Canada
- • Patient pipeline grows 10% to 1,528, backlog down 27% to 199 units, revenue up 26% in 2025 despite lower backlog
- • CMS reimbursement updated Jan 1, 2026 at approx. $68,800 for powered grasp (L8702 code), providing clearer payer framework
Management Discussion & Analysis
- • Revenue $40.9M in 2025, up 26% YoY from $32.6M driven by higher volume and ASP; direct billing $30.4M (74% of total, +20%), International $6.8M (+48%), U.S. O&P $2.9M (doubled), VA $0.8M (-31%)
- • Gross margin declined to 65.7% in 2025 from 71.2% in 2024, due to higher overhead capitalization changes and warranty expenses
- • Best performing segment: International with 48% growth to $6.8M; worst performing segment: VA with 31% decline to $0.8M
- • Cash used in operations $14.5M in 2025; capital expenditures approx. $3.3M including furniture, fixtures, and software; net proceeds $15.8M from Dec 2024 equity offering and $17.5M term loan facility raised in Nov 2025
- • 2026 outlook: focus on recurring revenues from MyoConnect referrals and O&P providers, reducing direct advertising costs, managing fixed expenses and improving gross margin through volume and cost reductions; risk from dependence on insurance reimbursement
Risk Factors
- • CMS reclassification of MyoPro to brace benefit category effective January 1, 2024 enabling lump sum reimbursement around $34,970 to $68,800 per device
- • Medicare Advantage plans reduced MyoPro authorizations causing 2% revenue decline in 2025; 20% of product revenues from these plans in 2025
- • Reliance on Cogmedix as sole contract manufacturer for key subassemblies risks supply delays, regulatory compliance issues, and costly transfer of production
- • Social media algorithm changes in Q1 2025 impaired lead generation, increasing advertising cost per addition to patient pipeline
- • Loan and Security Agreement with Avenue in Nov 2025 secures $17.5 million funding with covenants requiring $2.5 million minimum cash and 75% of projected revenue
MYOMO, INC. FY2025 Key Financial MetricsXBRL
Revenue
$41M
▲ +25.7% YoY
Net Income
-$16M
▼ -151.9% YoY
Gross Margin
65.7%
▼ -553bp YoY
Operating Margin
-35.2%
▼ -1612bp YoY
Net Margin
-38.1%
▼ -1905bp YoY
ROE
-136.6%
▼ -11155bp YoY
Total Assets
$39M
▼ -8.5% YoY
EPS (Diluted)
$-0.37
▼ -131.3% YoY
Operating Cash Flow
-$15M
▼ -341.1% YoY
Source: XBRL data from MYOMO, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on MYOMO, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.